share_log

Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy,...

Benzinga ·  Jun 28 23:41

Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy, Disease-Modifying Treatment; Phase 3 Studies Underway

Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS

  • Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
  • Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
  • Phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS (nrSPMS) are underway
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment